Study Finds Birth Hypoxia May Increase ADHD Likelihood
January 27, 2026
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Avastin,mvasi,zirabev,alymsys,vegzelma
Synonyms :
Class :
Antineoplastic, Vascular endothelial growth factor (VEGF) inhibitor
Brand Name :
Avastin,mvasi,zirabev,alymsys,vegzelma
Synonyms :
Class :
Antineoplastic, Vascular endothelial growth factor (VEGF) inhibitor
Dosage Forms & Strengths
Injectable solution:
25mg/ml (4ml,16ml-single vial dose)
In combination with fluorouracil chemotherapy:
Solution
Intravenous (IV)
every 2 weeks
(in combination with bolus-IFL (irinotecan, 5-FU, leucovorin))
IV:10mg/kg every two weeks (in combination with FOLFOX4)
Safety and efficacy not established
Refer adult dosing
may increase the risk of toxic effects when combined
may increase the immunosuppressive effects of each other
may increase the immunosuppressive effects of each other
may increase the immunosuppressive effects of each other
may increase the immunosuppressive effects of each other
may increase the immunosuppressive effects of each other
may increase the toxicity of each other
may increase the toxicity of each other
may increase the immunosuppressive effects of each other
may increase the risk or severity of adverse effects when combined
may increase the risk or severity of adverse effects when combined
may decrease serum potassium levels
may increase the risk of cardiotoxicity
may increase the risk of cardiotoxicity
may decrease the level of receptor binding competition
may increase the risk of cardiotoxicity
may increase the risk of cardiotoxicity
may increase the risk of diarrhea and neutropenia
may decrease the level of each other
may increase the immunosuppressive effects of each other
it may enhance the adverse effects when combined with aducanumab
It may diminish the effects when combined with rozanolixizumab by receptor binding competition
When bevacizumab is used together with capsaicin, this leads to enhanced risk or seriousness of methemoglobinemia
bevacizumab: it may increase the risk of methemoglobinemia agents
bevacizumab: it may increase the risk of methemoglobinemia agents
bevacizumab: it may increase the risk of methemoglobinemia agents
bevacizumab: it may increase the risk of methemoglobinemia agents
bevacizumab: it may increase the risk of methemoglobinemia agents
the risk or extent of adverse effects can be raised when bevacizumab is combined with technetium tc-99m arcitumomab
digitoxin may decrease the cardiotoxic activities of bevacizumab
Frequency defined:
>10%
Fatigue (72-80%)
Nausea (53-58%)
Arthralgia (33-41%)
Diarrhea (38-40%)
Headache (26-34%)
Hypertension (24-32%)
Decreased weight (20%)
Proteinuria (20%)
Myalgia (19%)
Back pain (12%)
Cough (12%)
Infusion-related reactions (11%)
Postoperative wound complications
1-10%
Arterial thrombosis (grades ≥3: 5%)
deep vein thrombosis (grades 3/4: 9%)
intra-abdominal venous thrombosis (grades 3/4: 3%)
left ventricular dysfunction (grades 3/4: 1%)
pulmonary embolism (1%)
syncope (grades 3/4: 3%)
thrombosis (10%)
Acne vulgaris (1%)
cellulitis (grades 3/4: 3%)
Dehydration (grades 3/4: 4%)
hypokalemia (grades 3/4: 7%)
Hemorrhage (grades ≥3: ≤7%; including major hemorrhage)
Bronchopleural fistula (≤2%)
nasal congestion (8%)
nasal signs and symptoms (7% to 10%)
rhinitis (≥3%)
rhinorrhea (10%)
1%
Antibody development
Reversible posterior leukoencephalopathy syndrome
Nephrotic syndrome
Frequency not defined:
Acute myocardial infarction
angina pectoris
Gastrointestinal hemorrhage
Hematemesis
Vaginal hemorrhage
Hypersensitivity reaction
Post-marketing report:
Polyserositis
Pulmonary hypertension
RPLS
mesenteric venous occlusion
Gastrointestinal ulcer
intestinal necrosis
Pancytopenia
No contraindications listed in the US manufacturing
Pregnancy consideration: The drug may cause fetal harm in pregnant women
Pregnancy category: AU TGA pregnancy category D
US FDA: Not assigned
Lactation: The excretion of the drug in human breast milk is unknown
Pregnancy category:
Patient information leaflet
Generic Name: bevacizumab
Pronounced: [ bev-a-CIZ-oo-mab]
Why do we use bevacizumab?
Bevacizumab is used to treat a specific type of brain tumor and certain types of kidneys, lung, rectum, and ovary cancer
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
